Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
about
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesDoes autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Stem cell transplantation in Hodgkin lymphoma.Relapsed Hodgkin lymphoma: management strategiesCurrent role of gemcitabine in the treatment of Hodgkin lymphoma.Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography evaluation of subcutaneous panniculitis-like T cell lymphoma and treatment response.The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.Emerging drugs for T-cell lymphoma.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomasGemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression.Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
P2860
Q33409608-FC110806-DCE2-4AB6-90FB-6A51536420A7Q33411127-1EE75875-480F-40B5-8D3A-70A0DFD55168Q33416550-42B0DD3D-FD1A-48E9-AAD1-FBDD4CF0C609Q33425005-39EC4F9D-5EAE-49C3-989E-349F6531448AQ33566475-61130C7B-0B30-4765-ADBD-656D6DF89D37Q36672691-074982F1-8D9C-4449-BF5F-F40E510991BBQ36752029-CD93431C-6732-4168-880D-F1DA16AAF222Q37008427-AAFC583E-5443-45CE-A2E1-B9227C977D4CQ37152761-612F613C-D08A-4802-BEBE-57B83C4BCCC3Q37247188-8AFE13FE-9DBD-42A7-B279-98C03FF1007DQ37824456-89EFE6FD-EAC6-4EB8-94A0-BB87F6DE0F75Q38196943-634027B9-111B-4FED-BAA8-941D5EF18CF5Q38912382-48CC190E-8E89-4350-82E4-4CD5F5AE2E69Q42323701-4B129B83-CCF4-4632-85CF-B38B580C7A9BQ43249154-B21F58AE-9470-43D7-B21C-4323D908B4AAQ43814680-D812B9FB-5878-493E-8490-4D12F3A65FE5Q44120728-00C9788F-D80A-4453-9C42-BA344FB95FC5Q44629491-8F88234F-F256-4486-AFF9-D85A7F335FEBQ46061398-F910CB87-EBD3-4C0A-8F04-6AA17C62B694Q53095626-06BC9723-0225-4853-8F76-5B55A0EDAE53Q53153689-C5FE073E-3611-4EBC-92B2-68DDD13AE90CQ53828417-D4F7C58E-2393-4C00-8F02-921AF92D15CC
P2860
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Gemcitabine, cisplatin and met ...... apsed and refractory lymphoma.
@ast
Gemcitabine, cisplatin and met ...... apsed and refractory lymphoma.
@en
type
label
Gemcitabine, cisplatin and met ...... apsed and refractory lymphoma.
@ast
Gemcitabine, cisplatin and met ...... apsed and refractory lymphoma.
@en
prefLabel
Gemcitabine, cisplatin and met ...... apsed and refractory lymphoma.
@ast
Gemcitabine, cisplatin and met ...... apsed and refractory lymphoma.
@en
P2093
P2860
P356
P1476
Gemcitabine, cisplatin and met ...... apsed and refractory lymphoma.
@en
P2093
A R Norman
A Wotherspoon
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602514
P407
P577
2005-04-01T00:00:00Z
P5875
P6179
1002994219